Jul 2026
Abstract B089: Targeting metabolic vulnerabilities in cancer through structure-guided discovery of novel malic enzyme inhibitors
These findings establish mitochondrial malic enzymes, particularly ME2/ME3, as tractable metabolic targets for cancer therapy, and provide a strong foundation for rational optimization of potency and isoform selectivity.
Ben A. Krinkel, Y. Yosaatmadja, M. Slayton et al.
· Clinical Cancer Research · 0 citations